Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Sabizabulin|DRUG: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Sponsor: Veru Inc.